GlyTR™ is an early stage biotech company developing an entirely new class of immunotherapeutic anti-cancer molecules and cells.
GlyTR™ Therapeutics is currently incubating at EvoNexus, Irvine.
About GlyTR Therapeutics
GlyTR Therapeutics is a novel immunotherapy technology that uniquely targets highly diverse cancer types, ranging from breast cancer to leukemia. GlyTR overcomes many of the shortcomings of current immunotherapies by binding to never-before targeted 'tumor associated carbohydrate antigens' that are abnormally expressed in virtually all types of cancer. GlyTR has the potential to increase efficacy over current immunotherapies and help save lives.
GlyTR Therapeutics is based on research that has come out of UC Irvine’s Research Labs. Professor and Inventor Dr. Michael Demetriou and Dr. Raymond Zhou are the scientists and founders of GlyTR Therapeutics. Their hard work and research over many years have culminated in a unique method to kill cancer cells across all types of cancers.
PROBLEMS with antibody based immunotherapies: